Q10 therapy in patients with idiopathic Parkinson's disease
Abstract
A 3-month open-label trial was performed to evaluate the efficacy of 200 mg Q10 daily in 10 patients with Parkinson's disease. Motor performance was assessed with UPDRS and motor tests. There was no significant effect on the clinical ratings.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Oral supplementation of 200 mg CoQ10 for three months did not bring any positive outcomes.
“Oral supplementation of 200 mg (which is considered a safe dose) for three months did not bring any positive outcomes (Strijks et al. 1997).”
From Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging (2023) · cites this paper as Strijks et al. 1997
Cites
Schapira, A. H. V., Mann, V. M., Cooper, J. A. D., Dexter, D. T., Daniel, S. E., Jenner, P. G., Clark, J. B., & MARSDEN, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb05809.x · Cited by 673 · see citing works
Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds
Tipton, K. F., & Singer, T. P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13610.x · Cited by 540 · see citing works
MARSDEN, C. D. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.6.672 · Cited by 384 · see citing works
Complex I Inhibitors Induce Dose‐Dependent Apoptosis in PC12 Cells: Relevance to Parkinson's Disease
Hartley, A., Stone, J. M., Heron, C., Cooper, J. A. D., & Schapira, A. H. V. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63051987.x · Cited by 361 · see citing works
Beal, M. F., Henshaw, D. R., Jenkins, B. G., Rosen, B. R., & Schulz, J. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360613 · Cited by 189 · see citing works
Coenzyme Q 10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease
Matthews, P. M., Ford, B., Dandurand, R. J., Eidelman, D. H., O'Connor, D., Sherwin, A. L., Karpati, G., Andermann, F., & Arnold, D. L. (1993) · Neurology · doi:10.1212/wnl.43.5.884 · Cited by 125 · see citing works
Schneider, H., Lemasters, J. J., & Hackenbrock, C. R. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)33893-6 · Cited by 110 · see citing works
Assessment of coenzyme q10 tolerability in huntington's disease
Feigin, A., Kieburtz, K. D., Como, P. G., Hickey, C., Abwender, D. A., Zimmerman, C., Steinberg, K., & Shoulson, I. (1996) · Movement Disorders · doi:10.1002/mds.870110317 · Cited by 108 · see citing works
Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q 10
Bresolin, N., Bet, L., Binda, A., Moggio, M. G., Comi, G. P., Nador, F., Ferrante, C., Carenzi, A., & Scarlato, G. (1988) · Neurology · doi:10.1212/wnl.38.6.892 · Cited by 107 · see citing works
Bendahan, D., Desnuelle, C., Vanuxem, D., Confort-Gouny, S., Figarella-Branger, D., Pellissier, J. F., Kozak-Ribbens, G., Pouget, J., Serratrice, G., & Cozzone, P. J. (1992) · Neurology · doi:10.1212/wnl.42.6.1203 · Cited by 104 · see citing works
Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity
Schulz, J. B., Ross Henshaw, D., Matthews, R. T., & Flint Beal, M. (1995) · Experimental Neurology · doi:10.1016/0014-4886(95)90033-0 · Cited by 103 · see citing works
Ubiquinone Protects Cultured Neurons against Spontaneous and Excitotoxin-Induced Degeneration
Favit, A., Nicoletti, F., Scapagnini, U., & Canonico, P. L. (1992) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1992.88 · Cited by 98 · see citing works
Singer, T. P., Ramsay, R. R., McKeown, K., Trevor, A., & Castagnoli, N. E. (1988) · Toxicology · doi:10.1016/0300-483x(88)90169-2 · Cited by 96 · see citing works
Isoprenoids in aging and neurodegeneration
Edlund, C., Söderberg, M. P., & Kristensson, K. (1994) · Neurochemistry International · doi:10.1016/0197-0186(94)90050-7 · Cited by 36 · see citing works
Which risk factors predict the levodopa response in fluctuating Parkinson's disease?
Horstink, M. W. I. M., Zijlmans, J. C. M., Pasman, J. W., Berger, H. J. C., Korten, J. J., & Hof, M. A. V. ’. (1990) · Annals of Neurology · doi:10.1002/ana.410270514 · Cited by 25 · see citing works
Self-citationFariello, R. G. (1988) · Neuropharmacology · doi:10.1016/0028-3908(88)90071-8 · Cited by 22 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638 · see citing works
- Authors
- Strijks, E., Kremer, H. P. H., & Horstink, M. W. I. M.
- Affiliations
- Radboud University Nijmegen (NL)
- ORCID
- Kremer, H.P.H.
- Venue
- Molecular Aspects of Medicine
- Publisher
- Elsevier BV
- Published
- 1997-01
- Volume
- 18
- Pages
- 237-240
- ISSN
- 0098-2997 (ISSN-L)
- OpenAlex
- W2002647820
- Cited by
- 45
- References
- 16
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 2 · 2017: 2 · 2015: 1 · 2014: 3 · 2012: 4
- FWCI
- 0.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Aspects of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
- Keywords
- Q10, coenzyme Q10, idiopathic Parkinson's disease, motor performance, Unified Parkinson's Disease Rating Scale, antioxidant therapy
- MeSH terms
- Aged, Antioxidants, Coenzymes, Humans, Middle Aged, Parkinson Disease, Psychomotor Performance, Severity of Illness Index, Ubiquinone, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
